TSE:4502Pharmaceuticals
What Is Drawing Fresh Attention To Takeda Pharmaceutical (TSE:4502)?
Takeda Pharmaceutical (TSE:4502) just cleared an important regulatory hurdle, with the U.S. FDA accepting its New Drug Application under Priority Review for zasocitinib in moderate to severe plaque psoriasis.
Buoyed by this regulatory milestone and other recent product updates, Takeda Pharmaceutical’s shares trade at ¥5,994, with a 7-day share price return of 5.79% and a 90-day share price return of 21.48%. The 1-year total shareholder return of 39.33% highlights the stock’s recent...